Last reviewed · How we verify
Pimasertib once daily
At a glance
| Generic name | Pimasertib once daily |
|---|---|
| Sponsor | EMD Serono |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer (PHASE2)
- Trial of MSC1936369B in Subjects With Solid Tumors (PHASE1)
- Combination Trial of Pimasertib (MSC1936369B) With Temsirolimus (PHASE1)
- Trial of Gemcitabine With or Without MSC1936369B in Pancreatic Cancer (PHASE1, PHASE2)
- Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors (PHASE1)
- MEK Inhibitor MSC1936369B Plus FOLFIRI in Second Line K-Ras Mutated Metastatic Colorectal Cancer (mCRC) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pimasertib once daily CI brief — competitive landscape report
- Pimasertib once daily updates RSS · CI watch RSS
- EMD Serono portfolio CI